IAP12 Rec'd PCT/FTO 18 JAN 2006

Express Mail: EV 630723091 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No:

To be assigned

Applicant:

VERMEIJ, P.

Confirmation No: Filed:

To be assigned January 18, 2006

Group Art Unit: Examiner:

To be assigned To be assigned

For:

Hybrid Toxins Comprising Shiga-Like Toxin Subunits Fused to

Eschericihia Coli Heat Labile Enterotoxin Subunits and Vaccines

Thereof

Attorney Docket:

I-2003.006 US

Corresponding to:

PCT/EP2004/051522, filed July 16, 2004

January 18, 2006

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97(b)

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-SB-08A and PTO-SB-08B. These references were cited in the parent case. Copies of the cited references are enclosed.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the last of (1) issuance of a first official action on the merits and (2) expiration of the three month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. It is respectfully requested that the

Page 1 of 2

U.S. National Phase of PCT/EP2004/051522

Appl. No. To be assigned

Attorney Docket: 1-2003.006 US Information Disclosure Statement Express Mail: EV 630723091 US

information be considered during the prosecution of this application and that the cited documents be listed on the front page of any patent issuing from this application.

Applicant directs the Examiner to EP 1057895 A1, which is not in English. This patent was cited in the International Search Report of the captioned application's corresponding International Application (i.e., PCT/EP2004/051522, filed July 16, 2004). A copy of this International Search Report is provided herewith.

Applicant does not believe that any other fee is due in connection with this filing. If, however, Applicant does owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **02-2334**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or 1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **02-2334**.

Applicant submits that this application is in condition for allowance, and requests that it be allowed. The Examiner is requested to call the Undersigned if any issues arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,

Aaron L. Schwartz,

PTO Reg. No: 48,181

Patent Counsel

Patent Department

Intervet Inc.

P.O. Box 318

29160 Intervet Lane

Millsboro, DE 19966

(302) 933-4034 (tel)

(302) 934-4305 (fax)

ALS:dap

10/565183

IAP12 Rec'd PCT/PTO 10 JAN 2006

Express Mail: EV 630723091 US

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** To be assigned Filing Date January 18, 2006 INFORMATION DISCLOSURE First Named Inventor VERMEIJ, Paul STATEMENT BY APPLICANT Art Unit To be assigned (Use as many sheets as necessary) **Examiner Name** To be assigned Attorney Docket Number I-2003.006 US Sheet 1 of |1

C	T 0:4-		U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (d known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	 	US-			- igares / tppear
	l				
		US-			
		US-			
		US-			<u> </u>
	<u> </u>	US-			
		US-			
		US-			
·		US-			
		US-	<u> </u>		
		US-			
	· · · · · · · · · · · · · · · · · · ·	US-			-
		US-			
		US-			
		US-	† 		
		US-			
		US-			
		US-			
		US-	-		
		US-	+ -		

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
		WO 01/70945 A1	09-27-2001	SIBTECH, INC		
		WO 01/89456 A2	11-29-2001	The Administrators of		
		EP 1 057 895 A1	12-06-2001	Lohmann Animal Health		
						L
	-					Ļ
						l

Examiner	Date	
Signature	Considered	
-		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/565183 IAP12 Rec'd PCT/FT0 18 JAN 2006

Express Mail: EV 630723091 US

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitu	te for form 1449/PTO			Complete if Known			
000000				Application Number	To be assigned		
INF	ORMATION	DIS	CLOSURE	Filing Date	January 18, 2006		
STATEMENT BY APPLICANT				First Named Inventor	VERMEIJ, Paul		
	(Use as many she	ote se n	acaeeand	Art Unit	To be assigned		
	(Ose as many sne	ets as II	ecessary)	Examiner Name	To be assigned		
Sheet	1	of	2	Attorney Docket Number	I-2003.006 US		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		ABHINEET S. SHEORAN ET AL., Stx2-Specific Human Monoclonal, Infection and Immunity, June 2003, p. 3125-3130, Vol.71 No.6, American Society for Microbiology, US	
		JEAN MUKHERJEE ET AL., Human Stx2-Specific Monoclonal Antibodies, Infection and Immunity, Feb. 2002, p.612-619, Vol. 70 No. 2, American Society for Microbiology, US	
		DAVID L. MACLEOD ET AL., Purification and Characterization of an, Infection and Immunity, May 1990, p.1232-1239, Vol. 58 No.5, American Society for Microbiology, US	
		FRANCES POUCH DOWNES ET AL., Affinity Purification and Characterization, Infection and Immunity, Aug. 1988, p. 1926-1933, Vol. 56 No.8, American Society for Microbiology	
		B. WOLFANGER BELISLE ET AL., Monoclonal Antibodies, Infection and Immunity, Dec. 1984, p. 759-764, Vol. 46 No. 3, American Society for Microbiology, US	
		B. WOLFANGER BELISLE ET AL., Characterization of Monoclonal, Infection and Immunity, March 1984, p. 1027-1032, Vol. 43 No. 3, American Society for Microbiology, US	
		CLAUDIA JEMAL ET AL., Analysis of Shiga Toxin, Journal of Bacteriology, June 1995, p.3128-3132, Vol. 177 No. 11, American Society for Microbiology, US	
		ANGELA R. MELTON-CELSA ET AL., Activation of Shiga toxin, Molecular Microbiology, 2002, p. 207-215, Vol. 43 No. 1, Blackwell Science, Ltd	
		CHIARA RODIGHIERO ET AL., Structural Basis for, The J. of Biological Chemistry, Feb. 12, 1999, p. 3962-3969, Vol. 274 No. 7, Amer. Soc. for Biochemistry and Molecular Bio.	
		MICHAEL MARTIN ET AL., Recombinant Antigen-Exterotoxin, Infection and Immunity, Jan. 2001, p. 252-261, Vol. 69 No. 1, American Society for Microbiology, US	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Express Mail: EV 630723091 US

10/565183 IAP12 Rec'd PCT/PTO 18 JAN 2006

	Approved for use inrough 07/31/2006. OMB 0651-0031
	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Panerwork Reduction Act of 1995	no persons are required to respond to a collection of information uplacs it contains a uplid OMP control our beautiful

	ite for form 1449/PTO		ot of 1550, 110 persons at	Complete if Known			
				Application Number	To be assigned		
			CLOSURE	Filing Date	January 18, 2006		
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	VERMEIJ, Paul		
	(Use as many she	ets as n	ecessary)	Art Unit	To be assigned		
				Examiner Name	To be assigned		
Sheet	2	of	2	Attorney Docket Number	I-2003.006 US		

		· · · · · · · · · · · · · · · · · · ·	
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MICHAEL G. JOBLING ET AL., Fusion Proteins Containing, Infection and Immunity, Nov. 1992, p. 4915-4924, Vol.60 No.11, American Society for Microbiology, US	
		ETHAN A. MERRITT ET AL., AB5 Toxins Current Opinion in Structural Biology, 1995, p.165-171, Vol. 5, Current Biology Ltd.	
		JAMES C. PATON ET AL., Pathogenesis and Diagnosis, Clinical Micro. Reviews, July 1998, p. 450-479, Vol. 11 No. 3, American Society for Microbiology, US	
		M. LEBENS ET AL., Synthesis of Hybrid Molecules, Infection and Immunity, June 1996, p. 2144-2150, Vol. 64 No. 6, American Society for Microbiology, US	

Examiner	Date		
Signature	Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.